Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review

References

• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–988.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82(suppl1):2N–9N.
   PubMed Web of Science ®Google Scholar
• Lip GY, Frison L, Halperin JL, et al. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 2010;41(12):2731–2738.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–2747.
   PubMed Web of Science ®Google Scholar
• January CT, Wann S, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the heart rhythm society. J Am Coll Cardiol. 2014;64(21):2246–2280.
   Web of Science ®Google Scholar
• Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864–2870.
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118(20):2029–2037.
   PubMed Web of Science ®Google Scholar
• Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638–645.
   PubMed Web of Science ®Google Scholar
• Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15:625–651.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–817.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363–2371.
   PubMed Web of Science ®Google Scholar
• EMA document. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf
   Google Scholar
• Lee WC, Lamas GA, Balu S, et al. Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective. J Med Econ. 2008;11(2):281–298.
   PubMedGoogle Scholar
• Biskupiak J, Ghate SR, Jiao T, et al. Cost implications of formulary decisions on oral anticoagulants in nonvalvular atrial fibrillation. J Manag Care Pharm. 2013;19(9):789–798.
   PubMed Web of Science ®Google Scholar
• Schulman S, Anderson DR, Bungard TJ, et al. Direct and indirect costs of management of long-term warfarin therapy in Canada. J Thromb Haemost. 2010;8:2192–2200.
   PubMed Web of Science ®Google Scholar
• Casciano JP, Dotiwala ZJ, Martin BC, et al. The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective. J Manag Care Pharm. 2013;19(4):302–316.
   PubMed Web of Science ®Google Scholar
• Lalibertè F, Cloutier M, Crivera C, et al. Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users. Clin Ther. 2015;37(3):554–562.
   PubMed Web of Science ®Google Scholar
• Deitelzweig S, Amin A, Jing Y, et al. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE- LY, ROCKET-AF, and ARISTOTLE trials. J Med Econ. 2012;15(4):776–785.
   PubMedGoogle Scholar
• Amin A, Deitelzweig S, Jing Y, et al. Comparison of medical costs of patients with atrial fibrillation unsuitable for warfarin treatment with apixaban or aspirin based on AVERROES trial. Clin Appl Thromb Hemost. 2015;21(3):235–240.
   PubMed Web of Science ®Google Scholar
• Glanville J, Paisley S. Identifying economic evaluations for health technology assessment. Int J Technol Assess Health Care. 2010;26(4):436–440.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. CHEERS task force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Int J Technol Assess Health Care. 2013;29(2):117–122.
   PubMed Web of Science ®Google Scholar
• Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154(1):1–11.
   PubMed Web of Science ®Google Scholar
• Pink J, Lane S, Pirmohamed M, et al. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ. 2011;343:d6333.
   PubMed Web of Science ®Google Scholar
• Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123:2562–2570.
   PubMed Web of Science ®Google Scholar
• Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost. 2011;105(5):908–919.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Juanatey JR, Alvarez-Sabin J, Lobos JM, et al. Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain. Rev Esp Cardiol. 2012;65(10):901–910.
   PubMed Web of Science ®Google Scholar
• Kamel H, Easton JD, Johnston SC, et al. Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation. Neurology. 2012;79(14):1428–1434.
   PubMed Web of Science ®Google Scholar
• Kamel H, Johnston SC, Easton JD, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke. 2012;43(3):881–883.
   PubMed Web of Science ®Google Scholar
• Kansal AR, Sharma M, Bradley-Kennedy C, et al. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness. Thromb Haemost. 2012;108(4):672–682.
   PubMed Web of Science ®Google Scholar
• Kansal AR, Sorensen SV, Gani R, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart. 2012;98(7):573–578.
   PubMed Web of Science ®Google Scholar
• Langkilde LK, Bergholdt Asmussen M, Overgaard M. Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark. J Med Econ. 2012;15(4):695–703.
   PubMedGoogle Scholar
• Lee S, Anglade MW, Meng J, et al. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin. Circ Cardiovasc Qual Outcomes. 2012;5(4):472–479.
   PubMed Web of Science ®Google Scholar
• Lee S, Anglade MW, Pham D, et al. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol. 2012;110(6):845–851.
   PubMed Web of Science ®Google Scholar
• Lee S, Mullin R, Blazawski J, et al. Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. PloS One. 2012;7(10):e47473. doi:10.1371/journal.pone.0047473.
   Google Scholar
• You JHS, Tsui KKN, Wong RSM, et al. Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation. PloS One. 2012;7(6):e39640. doi:10.1371/journal.pone.0039640.
   PubMed Web of Science ®Google Scholar
• Ademi Z, Pasupathi K, Liew D. Cost-effectiveness of apixaban compared to in the management of atrial fibrillation in Australia. Eur J Prev Cardiol. 2013; published online 26 November 2013. doi:10.1177/2047487313514019
   PubMed Web of Science ®Google Scholar
• Andrikopoulos GK, Fragoulakis V, Maniadakis N. Economic evaluation of dabigatran etexilate in the management of atrial fibrillation in Greece. Hellenic J Cardiol. 2013;54(4):289–300.
   PubMed Web of Science ®Google Scholar
• Bergh M, Marais CA, Miller-Janson H, et al. Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation. S Afr Med J. 2013;103(4):241.5.
   PubMed Web of Science ®Google Scholar
• Canestaro WJ, Patrick AR, Avorn J, et al. Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2013;6(6):724–731.
   PubMed Web of Science ®Google Scholar
• Coyle D, Coyle K, Cameron C, et al. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value Health. 2013;16(4):498–506.
   PubMed Web of Science ®Google Scholar
• Davidson T, Husberg M, Janzon M, et al. Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden. Eur Heart J. 2013;34(3):177–183.
   PubMed Web of Science ®Google Scholar
• Harrington AR, Armstrong EP, Nolan PE Jr, et al. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke. 2013;44(6):1676–1681.
   PubMed Web of Science ®Google Scholar
• Kleintjens J, Li X, Simoens S, et al. Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting. Pharmacoeconomics. 2013;31(10):909–918.
   PubMed Web of Science ®Google Scholar
• Nshimyumukiza L, Duplantie J, Gagnon M, et al. Dabigatran versus warfarin under standard or pharmacogenetic-guided management for prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model. Thromb J. 2013;11(1):14.
   PubMedGoogle Scholar
• Pletscher M, Plessow R, Eischler K, et al. Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland. Swiss Med Wkly. 2013;143:w13732.
   PubMed Web of Science ®Google Scholar
• Singh SM, Micieli A, Wijeysundera HC. Economic evaluation of percutaneous left atria appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. Circulation. 2013;127(24):2414–2423.
   PubMed Web of Science ®Google Scholar
• Wouters H, Thijs V, Annemans L. Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium. J Med Econ. 2013;16(3):407–414.
   PubMedGoogle Scholar
• Baron Esquivias G, Escolar Albaladejo G, Zamorano JL, et al. Cost-effectiveness analysis comparing apixaban and acenocoumarol in the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain. Rev Esp Cardiol. 2014; published online 6 December 2014. doi:10.1016/j.rec.2014.08.010.
   Web of Science ®Google Scholar
• Chang CH, Yang YH, Chen JH, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan. Thromb Res. 2014;133(5):782–789.
   PubMed Web of Science ®Google Scholar
• Chevalier J, Delaitre O, Hammès F, et al. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective. Arch Cardiovasc Dis. 2014;107(6–7):381–390.
   PubMed Web of Science ®Google Scholar
• Clemens A, Peng S, Brand S, et al. Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups. Am J Cardiol. 2014;114(6):849–855.
   PubMed Web of Science ®Google Scholar
• Dorian P, Kongnakorn T, Phatak H, et al. Cost-effectiveness of apixaban vs current standard of care for stroke prevention in patients with atrial fibrillation. Eur Heart J. 2014;35(28):1897–1906.
   PubMed Web of Science ®Google Scholar
• Janzic A, Kos M. Cost-effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control. Pharmacoeconomics. 2014; published online 16 December 2014. doi:10.1007/s40273-014-0246-7
   Web of Science ®Google Scholar
• Kongnakorn T, Lanitis T, Annemans L, et al. Stroke and systemic embolism prevention in patients with atrial fibrillation in Belgium: comparative effectiveness of new oral anticoagulants and warfarin. Clin Drug Invest. 2014; published online 16 December 2014. doi:10.1007/s40261-014-0253-7.
   PubMed Web of Science ®Google Scholar
• Kongnakorn T, Lanitis T, Annemans L, et al. Cost-effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in Belgium. Clin Drug Invest. 2014;34(10):709–721.
   PubMed Web of Science ®Google Scholar
• Kourlaba G, Maniadakis N, Andrikopoulos G, et al. Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece. Cost Eff Resource Alloc. 2014;12(1):5.
   PubMedGoogle Scholar
• Krejczy M, Harenberg J, Marx S, et al. Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries. J Thromb Thrombolysis. 2014;37(4):507–523.
   PubMed Web of Science ®Google Scholar
• Lanitis T, Kongnakorn T, Jacobson L, et al. Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation. Tromb Res. 2014;134(2):278–287.
   PubMed Web of Science ®Google Scholar
• Lanitis T, Cotté FE, Gaudin AF, et al. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin. J Med Econ. 2014;17(8):587–598.
   PubMedGoogle Scholar
• Lip GYH, Kongnakorn T, Phatak H, et al. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. Clin Ther. 2014;36(2):192–210.
   PubMed Web of Science ®Google Scholar
• Mensch A, Stock S, Stollenwerk B, et al. Cost-effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation. Pharmacoeconomics. 2014; published online 18 December 2014. doi:10.1007/s40273-014-0236-9
   Web of Science ®Google Scholar
• Morais J, Aguiar C, McLeod E, et al. Cost-effectiveness of rivaroxaban in atrial fibrillation in the Portuguese setting. Rev Port Cardiol. 2014;333(9):535–544.
   Google Scholar
• Pink J, Pirmohamed M, Lane S, et al. Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation. Clin Pharmacol Ther. 2014;95(2):199–207.
   PubMed Web of Science ®Google Scholar
• Rognoni C, Marchetti M, Quaglini S, et al. Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. Clin Drug Investig. 2014;34(1):9–17.
   PubMed Web of Science ®Google Scholar
• Rognoni C, Marchetti M, Quaglini S, et al. Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. J Thromb Thrombolysis. 2014; published online 28 June 2014. doi:10.1007/s11239-014-1104-3
   Web of Science ®Google Scholar
• Stevanović J, Pompen M, Le HH, et al. Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands. PLoS ONE. 2014;9(8):e103974. doi:10.1371/journal.pone.0103974.
   PubMed Web of Science ®Google Scholar
• Verhoef TI, Redekop WK, Hasrat F, et al. Cost-effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings. Am J Cardiovasc Drugs. 2014;14(6):451–462.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xie F, Kong MC, et al. Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation. Cardiovasc Drug Ther. 2014;28(6):575–585.
   PubMed Web of Science ®Google Scholar
• Wisløff T, Hagen G, Klemp M. Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation. Pharmacoeconomics. 2014;32(6):601–612.
   PubMed Web of Science ®Google Scholar
• Wu B, Kun L, Liu X, et al. Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting. Cradiovasc Drugs Ther. 2014;28(1):87–98.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Sorensen SV, Gonschior AK, et al. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting. Clin Ther. 2014;36(12):2015–2028.
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Antithrombotic agents for the prevention of stroke and systemic embolism in patients with atrial fibrillation [Internet]. Ottawa: The Agency; 2013. (CADTH Therapeutic Review; vol.1, no. 1b). [ cited 2015 Sep 15]. Available from: http://www.cadth.ca/media/pdf/TR0003_AntithromboticAgents-AF_ScienceReport_e.pdf.
   Google Scholar
• NICE technology appraisal guidance 249. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation. [ cited 2015 Sep 15]. Available from: https://www.nice.org.uk/guidance/ta249/resources/guidance-dabigatran-etexilate-for-the-prevention-of-stroke-and-systemic-embolism-in-atrial-fibrillation-pdf.
   Google Scholar
• NICE technology appraisal guidance 256. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation. [ cited 2015 Sep 15]. Available from: https://www.nice.org.uk/guidance/ta256/resources/guidance-rivaroxaban-for-the-prevention-of-stroke-and-systemic-embolism-in-people-with-atrial-fibrillation-pdf.
   Google Scholar
• NICE technology appraisal guidance 275. Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation. [ cited 2015 Sep 15]. Available from: https://www.nice.org.uk/guidance/ta275/resources/guidance-apixaban-for-preventing-stroke-and-systemic-embolism-in-people-with-nonvalvular-atrial-fibrillation-pdf.
   Google Scholar
• Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost. 2012;108(3):476–484.
   PubMed Web of Science ®Google Scholar
• Fu W, Guo H, Lin K, et al. Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysis. J Cardiovasc Med. 2014;15(12):873–879.
   Google Scholar
• White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and IV. Arch Intern Med. 2007;167(3):239–245.
   PubMedGoogle Scholar
• NICE clinical guideline 180 275. Atrial fibrillation: the management of atrial fibrillation. [ cited 2015 Sep 15]. Available from: https://www.nice.org.uk/guidance/cg180/resources/guidance-atrial-fibrillation-the-management-of-atrial-fibrillation-pdf.
   Google Scholar
• Pokorney SD, Simon DN, Thomas L, et al. Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: results from ORBIT-AF registry. Am Heart J. 2015;170(1):141–148.
   PubMed Web of Science ®Google Scholar
• Macedo AF, Bell J, McCarron C, et al. Determinants of oral anticoagulation control in new warfarin patients: analysis using data from Clinical Practice Research Datalink. Thromb Res. 2015;132(2):250–260.
   Web of Science ®Google Scholar
• Cottè FE, Benhaddi H, Duprat-Lornon I, et al. Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countries. Clin Ther. 2014;36(9):1160–1168.
   PubMed Web of Science ®Google Scholar
• Hernandez I, Baik SH, Piñera A, et al. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2015;175(1):18–24.
   PubMed Web of Science ®Google Scholar
• Abraham NS, Singh S, Alexander GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 2015;350:h1857.
   PubMed Web of Science ®Google Scholar